What are the best practices for building a drug diversion prevention program in healthcare organizations?

Effective drug diversion prevention works best as a holistic program, not a single control. Health delivery organizations should combine trained staffing, diversion investigation processes, employee education on substance use disorder, rehabilitation resources, and automation tools. The goal is to detect suspicious medication activity earlier, support remediation faster, and reduce the patient safety, compliance, and reputational impact of diversion.

What a healthcare drug diversion prevention program actually needs

A strong program starts with clear ownership, a defined diversion policy, and a practical operating model for how suspicious activity is identified, reviewed, and escalated. In healthcare, diversion prevention is not just an inventory problem, it is a patient safety, workforce, compliance, and trust problem. The best programs connect clinical operations, pharmacy, security, HR, compliance, and leadership.

The most effective programs treat diversion as a lifecycle issue: prevention, detection, investigation, intervention, and recovery. That means having documented procedures for controlled substance handling, access review, discrepancy analysis, incident response, and employee support. It also means making sure the program can work at the scale and pace of real medication workflows, not only during periodic audits.

A useful program also balances control with usability. If the process is too slow or too punitive, staff may route around it, underreport concerns, or miss early warning signs. If it is too loose, the organization creates gaps that can hide theft, substitution, tampering, or repeated small losses that only become visible much later.

Which controls make diversion harder to hide?

Core controls should focus on reducing opportunity and improving traceability. Common building blocks include role-based access to medication storage and dispensing, independent witness requirements where appropriate, reconciliations between dispensing and administration records, anomaly review for wasting and overrides, and periodic physical counts for high-risk inventories. Strong logging matters because diversion often leaves a trail in access, transaction, and documentation data even when the medication itself is not immediately missing.

Automation can materially improve detection when it is used to correlate data that humans cannot review consistently at scale. Patterns such as repeated waste events, unusual night-shift activity, frequent access to specific substances, or discrepancies between dispensing and administration records are exactly the sort of signals that benefit from rules, workflow alerts, and exception queues. The key is that automation should support trained review, not replace judgment.

Controls work best when they are layered. Inventory controls without access controls are easy to work around, while access controls without investigative follow-up create alerts that go nowhere. The highest-value programs make each control answer a different question: who had access, what was taken, whether it was administered, whether the pattern is normal, and who must review the exception.

How should organizations handle suspicion, disclosure, and recovery?

A mature program distinguishes between detection, fact finding, and response. Suspicion should trigger a consistent case workflow, not improvisation. That workflow usually includes preserving records, limiting further exposure where necessary, validating chain-of-custody evidence, and coordinating the right functions before making conclusions. The investigation process should be designed to support both safety and fairness, because false positives can harm staff and weaken trust in the program.

Employee education is not optional. Staff need to understand what diversion looks like in practice, how to report concerns, and why early reporting protects patients and colleagues. Organizations also need a defined path for rehabilitation and return-to-work decisions when substance use disorder is part of the picture. Programs that only emphasize punishment often lose visibility, while programs that combine accountability with support are more likely to surface concerns sooner.

Leadership should define escalation thresholds in advance. A single missing dose, a repeated pattern of discrepancies, or evidence of tampering may require different actions, but all should have an owner, a response timeline, and a documented outcome. Without that discipline, even a well-designed program becomes inconsistent and hard to defend.

Risk and Threat Considerations

drug diversion creates both direct harm and control failure. The risk is not limited to loss of controlled substances, because undetected diversion can expose patients to inadequate pain control, substitution, contamination, delayed treatment, and broader confidence loss in clinical processes.

Failure mechanism: Diversion often succeeds through small, repeated exceptions, weak reconciliation, poor visibility into wasting and overrides, or cultural reluctance to question trusted staff. Once those gaps exist, the same person can continue exploiting them for a long time before a pattern becomes obvious.

Impact: The organization can face patient safety incidents, regulatory findings, workforce disruption, reputational damage, and a much larger investigative burden after the fact. If the program cannot explain who saw what, when, and why action was or was not taken, it will struggle to contain the event and learn from it.

Standards & Framework Alignment

This section maps relevant standards and security frameworks to the operational risks and controls described in this guidance.

NIST SP 800-53 Rev 5 and NIST CSF 2.0 set the technical controls, while ISO/IEC 27001:2022 defines the regulatory obligations.

Framework	Control / Reference	Relevance
NIST SP 800-53 Rev 5	AU-6 — Audit Record Review, Analysis, and Reporting	Diversion programs rely on reviewing logs and discrepancies to spot suspicious controlled-substance activity.
	AC-6 — Least Privilege	Controlled-substance handling depends on limiting who can access, waste, or override medication processes.
	PS-3 — Personnel Screening	Diversion prevention depends on trust-aware staffing and accountability for people handling controlled substances.
Recommendation — Review access, dispensing, and waste records for anomalies and escalate exceptions promptly. Restrict medication access to the minimum roles needed for clinical work. Screen personnel in sensitive medication roles and reassess access when risk changes.
NIST CSF 2.0	DE.CM-01 — Anomalies and Events Are Monitored	The program needs ongoing monitoring for abnormal medication access and waste patterns.
	GV.RM-01 — Risk Management Strategy	Diversion prevention requires an organization-level strategy that aligns safety, compliance, and response.
Recommendation — Monitor medication workflows continuously for anomalous activity and route exceptions to review. Define how diversion risk is owned, tolerated, escalated, and reviewed across the organization.
ISO/IEC 27001:2022	A.5.15 — Access control	Controlled-substance handling needs formal rules for who can access medication systems and storage.
	A.5.24 — Information security incident management planning and preparation	Diversion investigations require a prepared process for handling suspected incidents consistently.
	A.6.8 — Information security event reporting	Staff must know how to report suspected diversion events without delay or ambiguity.
Recommendation — Apply formal access control rules to medication systems, stores, and exception workflows. Prepare an incident workflow for suspected diversion, evidence preservation, and escalation. Define and train a clear reporting path for suspected medication diversion events.

Practitioner Guidance

What to prioritize: Start with the substances, workflows, and units that combine high clinical risk and high opportunity for concealment, such as frequent dispensing, wasting, overrides, or high-volume handoffs. That is where a program usually gets the earliest return on effort.

What to verify: Make sure every alert can be traced to an owner, a decision, and a follow-up outcome. If the organization cannot show that a suspicious event was reviewed consistently, the control is only producing noise.

What good looks like: The program produces timely exceptions, clear case ownership, documented disposition, and enough support for staff that reporting feels safer than silence. The goal is early visibility and durable accountability, not just more monitoring.

Practitioner takeaway: The most effective diversion programs are designed as operating systems for action, not compliance checklists, they combine traceable controls, trained review, and supportive intervention so that early warning signs become measurable decisions instead of unresolved suspicion.